To include your compound in the COVID-19 Resource Center, submit it here.

Bellus Health, Celtic Therapeutics Holdings L.P. deal

Bellus granted Celtic Therapeutics exclusive, worldwide rights to Kiacta eprodisate. Celtic will fund development

Read the full 144 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE